NASDAQ: ATYR
Atyr Pharma Inc Stock Ownership - Who owns Atyr Pharma?

Insider buying vs selling

Have Atyr Pharma Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Jane A. GrossDirector2025-03-173,750$4.00
$15.00kBuy
Jill Marie BroadfootChief Financial Officer2025-02-041,254$3.78
$4.74kSell
Nancy DenyesGeneral Counsel2025-02-04899$3.78
$3.40kSell

1 of 1

ATYR insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when ATYR insiders and whales buy or sell their stock.

ATYR Shareholders

What type of owners hold Atyr Pharma Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Federated Hermes Inc16.48%14,666,600$76.85MInstitution
Fmr LLC15.00%13,350,665$69.96MInstitution
Blackrock Inc6.50%5,782,633$30.30MInstitution
Vanguard Group Inc5.23%4,655,048$24.39MInstitution
Octagon Capital Advisors LP4.29%3,820,000$20.02MInstitution
Tikvah Management LLC2.76%2,460,833$12.89MInstitution
Geode Capital Management LLC2.36%2,098,076$10.99MInstitution
Srinivas Akkaraju2.10%1,866,126$9.78MInsider
Sofinnova Venture Partners IX LP2.10%1,866,126$9.78MInsider
Amir Nashat2.07%1,840,564$9.64MInsider

1 of 3

ATYR vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
ATYR74.54%17.28%Net Buying
NBTX11.90%0.00%
REPL66.02%33.98%Net SellingNet Selling
RGNX77.01%22.99%Net SellingNet Selling
ERAS71.73%28.27%Net Buying

Atyr Pharma Stock Ownership FAQ

Who owns Atyr Pharma?

Atyr Pharma (NASDAQ: ATYR) is owned by 74.54% institutional shareholders, 17.28% Atyr Pharma insiders, and 8.18% retail investors. Srinivas Akkaraju is the largest individual Atyr Pharma shareholder, owning 1.87M shares representing 2.10% of the company. Srinivas Akkaraju's Atyr Pharma shares are currently valued at $9.82M.

If you're new to stock investing, here's how to buy Atyr Pharma stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.